サマリー

二重鎖抗体薬の世界市場規模は、2025年の100万米ドルから2031年には100万米ドルに成長すると予測されており、2025年から2031年までの年平均成長率は%であると予測されています。
二重鎖抗体薬の米国市場は、2024年の百万米ドルから2031年には百万米ドルに増加し、2025年から2031年までの年平均成長率は％と予測されています。
二重鎖抗体薬の中国市場は、2024年の100万米ドルから2031年には100万米ドルに、2025年から2031年までの年平均成長率は％と推定される。
二重鎖抗体薬のヨーロッパ市場は、2025年から2031年までの年平均成長率%で、2024年の百万米ドルから2031年には百万米ドルに増加すると推定される。
二重鎖抗体薬の世界的な主要企業は、Amgen Inc.、F. Hoffman La Roche Ltd.、AbbVie Inc.、OncoMed Pharmaceuticals, Inc.、Glenmark Pharmaceuticals Limitedなどをカバーしています。売上高では、2024年には世界の大手2社がほぼ％のシェアを占める。
LPインフォメーション社の最新調査レポート「二重鎖抗体医薬品産業予測」は、過去の売上高と2024年の二重鎖抗体医薬品の世界総売上高に注目し、2025年から2031年までの二重鎖抗体医薬品の予測売上高を地域別・市場分野別に包括的に分析しています。本レポートでは、二重鎖抗体薬の売上高を地域別、市場分野別、サブセクター別に分類し、世界の二重鎖抗体薬産業の詳細な分析を百万米ドル単位で提供しています。
本インサイトレポートは、世界の二重バレル抗体医薬品の状況を包括的に分析し、製品区分、企業形成、収益、市場シェア、最新開発、M&A活動に関する主要動向を明らかにします。また、本レポートでは、加速する世界の二重抗体医薬品市場におけるこれらの企業の独自のポジションをより良く理解するために、二重抗体医薬品のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、主要グローバル企業の戦略を分析しています。
本インサイトレポートは、二重鎖抗体薬の世界的な展望を形成する主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、本調査予測は、世界の二重バレル抗体医薬品の現状と将来の軌跡について非常にニュアンスのある見解を提供します。
当レポートでは、製品タイプ別、用途別、主要メーカー別、主要地域別および国別の二重バレル抗体医薬品市場の包括的な概要、市場シェア、成長機会を提示しています。
タイプ別セグメント
除去剤
ブリンサイト
その他
用途別セグメント
肺がん
脳腫瘍
肝臓がん
その他
本レポートではまた、市場を地域別に分けています：
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
アムジェン
F.ホフマン・ラ・ロシュ社
アッヴィ
オンコメッド社
グレンマーク・ファーマシューティカルズ・リミテッド
ゼンコール社
マクロジェニックス社
アプテボ・セラピューティクス社
リガンド・ファーマシューティカルズ・インク
リジェネロン社
フレゼニウス SE & Co.KGaA
メルスN.V.
本レポートで扱う主な質問
二重鎖抗体薬の世界市場の10年見通しは？
世界および地域別で、二重鎖抗体薬市場の成長を促進する要因は何か？
市場別・地域別に最も急成長する技術は何か？
二重バレル抗体医薬品の市場機会は最終市場規模によってどのように異なるのか？
二重バレル抗体医薬品のタイプ別、用途別の内訳は？

ページTOPに戻る

目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Double Barreled Antibodies Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Double Barreled Antibodies Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Double Barreled Antibodies Drug by Country/Region, 2020, 2024 & 2031
2.2 Double Barreled Antibodies Drug Segment by Type
2.2.1 Removab
2.2.2 BLINCYTO
2.2.3 Others
2.3 Double Barreled Antibodies Drug Sales by Type
2.3.1 Global Double Barreled Antibodies Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Double Barreled Antibodies Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Double Barreled Antibodies Drug Sale Price by Type (2020-2025)
2.4 Double Barreled Antibodies Drug Segment by Application
2.4.1 Lung Cancer
2.4.2 Brain Cancer
2.4.3 Liver Cancer
2.4.4 Others
2.5 Double Barreled Antibodies Drug Sales by Application
2.5.1 Global Double Barreled Antibodies Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Double Barreled Antibodies Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Double Barreled Antibodies Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Double Barreled Antibodies Drug Breakdown Data by Company
3.1.1 Global Double Barreled Antibodies Drug Annual Sales by Company (2020-2025)
3.1.2 Global Double Barreled Antibodies Drug Sales Market Share by Company (2020-2025)
3.2 Global Double Barreled Antibodies Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Double Barreled Antibodies Drug Revenue by Company (2020-2025)
3.2.2 Global Double Barreled Antibodies Drug Revenue Market Share by Company (2020-2025)
3.3 Global Double Barreled Antibodies Drug Sale Price by Company
3.4 Key Manufacturers Double Barreled Antibodies Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Double Barreled Antibodies Drug Product Location Distribution
3.4.2 Players Double Barreled Antibodies Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Double Barreled Antibodies Drug by Geographic Region
4.1 World Historic Double Barreled Antibodies Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Double Barreled Antibodies Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Double Barreled Antibodies Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Double Barreled Antibodies Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Double Barreled Antibodies Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Double Barreled Antibodies Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Double Barreled Antibodies Drug Sales Growth
4.4 APAC Double Barreled Antibodies Drug Sales Growth
4.5 Europe Double Barreled Antibodies Drug Sales Growth
4.6 Middle East & Africa Double Barreled Antibodies Drug Sales Growth
5 Americas
5.1 Americas Double Barreled Antibodies Drug Sales by Country
5.1.1 Americas Double Barreled Antibodies Drug Sales by Country (2020-2025)
5.1.2 Americas Double Barreled Antibodies Drug Revenue by Country (2020-2025)
5.2 Americas Double Barreled Antibodies Drug Sales by Type (2020-2025)
5.3 Americas Double Barreled Antibodies Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Double Barreled Antibodies Drug Sales by Region
6.1.1 APAC Double Barreled Antibodies Drug Sales by Region (2020-2025)
6.1.2 APAC Double Barreled Antibodies Drug Revenue by Region (2020-2025)
6.2 APAC Double Barreled Antibodies Drug Sales by Type (2020-2025)
6.3 APAC Double Barreled Antibodies Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Double Barreled Antibodies Drug by Country
7.1.1 Europe Double Barreled Antibodies Drug Sales by Country (2020-2025)
7.1.2 Europe Double Barreled Antibodies Drug Revenue by Country (2020-2025)
7.2 Europe Double Barreled Antibodies Drug Sales by Type (2020-2025)
7.3 Europe Double Barreled Antibodies Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Double Barreled Antibodies Drug by Country
8.1.1 Middle East & Africa Double Barreled Antibodies Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Double Barreled Antibodies Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Double Barreled Antibodies Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Double Barreled Antibodies Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Double Barreled Antibodies Drug
10.3 Manufacturing Process Analysis of Double Barreled Antibodies Drug
10.4 Industry Chain Structure of Double Barreled Antibodies Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Double Barreled Antibodies Drug Distributors
11.3 Double Barreled Antibodies Drug Customer
12 World Forecast Review for Double Barreled Antibodies Drug by Geographic Region
12.1 Global Double Barreled Antibodies Drug Market Size Forecast by Region
12.1.1 Global Double Barreled Antibodies Drug Forecast by Region (2026-2031)
12.1.2 Global Double Barreled Antibodies Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Double Barreled Antibodies Drug Forecast by Type (2026-2031)
12.7 Global Double Barreled Antibodies Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Amgen Inc.
13.1.1 Amgen Inc. Company Information
13.1.2 Amgen Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.1.3 Amgen Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Amgen Inc. Main Business Overview
13.1.5 Amgen Inc. Latest Developments
13.2 F. Hoffman La Roche Ltd.
13.2.1 F. Hoffman La Roche Ltd. Company Information
13.2.2 F. Hoffman La Roche Ltd. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.2.3 F. Hoffman La Roche Ltd. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 F. Hoffman La Roche Ltd. Main Business Overview
13.2.5 F. Hoffman La Roche Ltd. Latest Developments
13.3 AbbVie Inc.
13.3.1 AbbVie Inc. Company Information
13.3.2 AbbVie Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.3.3 AbbVie Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 AbbVie Inc. Main Business Overview
13.3.5 AbbVie Inc. Latest Developments
13.4 OncoMed Pharmaceuticals, Inc.
13.4.1 OncoMed Pharmaceuticals, Inc. Company Information
13.4.2 OncoMed Pharmaceuticals, Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.4.3 OncoMed Pharmaceuticals, Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 OncoMed Pharmaceuticals, Inc. Main Business Overview
13.4.5 OncoMed Pharmaceuticals, Inc. Latest Developments
13.5 Glenmark Pharmaceuticals Limited
13.5.1 Glenmark Pharmaceuticals Limited Company Information
13.5.2 Glenmark Pharmaceuticals Limited Double Barreled Antibodies Drug Product Portfolios and Specifications
13.5.3 Glenmark Pharmaceuticals Limited Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Glenmark Pharmaceuticals Limited Main Business Overview
13.5.5 Glenmark Pharmaceuticals Limited Latest Developments
13.6 Xencor, Inc.
13.6.1 Xencor, Inc. Company Information
13.6.2 Xencor, Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.6.3 Xencor, Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Xencor, Inc. Main Business Overview
13.6.5 Xencor, Inc. Latest Developments
13.7 MacroGenics, Inc.
13.7.1 MacroGenics, Inc. Company Information
13.7.2 MacroGenics, Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.7.3 MacroGenics, Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 MacroGenics, Inc. Main Business Overview
13.7.5 MacroGenics, Inc. Latest Developments
13.8 Aptevo Therapeutics Inc.
13.8.1 Aptevo Therapeutics Inc. Company Information
13.8.2 Aptevo Therapeutics Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.8.3 Aptevo Therapeutics Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Aptevo Therapeutics Inc. Main Business Overview
13.8.5 Aptevo Therapeutics Inc. Latest Developments
13.9 Ligand Pharmaceuticals, Inc.
13.9.1 Ligand Pharmaceuticals, Inc. Company Information
13.9.2 Ligand Pharmaceuticals, Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.9.3 Ligand Pharmaceuticals, Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Ligand Pharmaceuticals, Inc. Main Business Overview
13.9.5 Ligand Pharmaceuticals, Inc. Latest Developments
13.10 Regeneron Pharmaceuticals, Inc.
13.10.1 Regeneron Pharmaceuticals, Inc. Company Information
13.10.2 Regeneron Pharmaceuticals, Inc. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.10.3 Regeneron Pharmaceuticals, Inc. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
13.10.5 Regeneron Pharmaceuticals, Inc. Latest Developments
13.11 Fresenius SE & Co. KGaA
13.11.1 Fresenius SE & Co. KGaA Company Information
13.11.2 Fresenius SE & Co. KGaA Double Barreled Antibodies Drug Product Portfolios and Specifications
13.11.3 Fresenius SE & Co. KGaA Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Fresenius SE & Co. KGaA Main Business Overview
13.11.5 Fresenius SE & Co. KGaA Latest Developments
13.12 Merus N.V.
13.12.1 Merus N.V. Company Information
13.12.2 Merus N.V. Double Barreled Antibodies Drug Product Portfolios and Specifications
13.12.3 Merus N.V. Double Barreled Antibodies Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Merus N.V. Main Business Overview
13.12.5 Merus N.V. Latest Developments
14 Research Findings and Conclusion